NVAX : Successful Preclinical Study of Bird Flu Vaccines;
Enviado: 23/1/2007 21:41Premarket Movers: Novavax Rises
Tuesday January 23, 9:14 am ET
Novavax Up on Successful Preclinical Study of Bird Flu Vaccines; Nasdaq Declines
Among the most active stocks was Novavax Inc., which added 41 cents, or 10 percent, to $4.50 in premarket electronic trading after the Malvern, Pa., biotech drug developer said its virus-like particle vaccines were effective in preclinical studies in protecting against different strains of the H5N1 bird flu virus.
Studies involved two vaccines. One targets the Indonesia strain of avian flu and another targets the Vietnam strain.
The stock closed at $4.09 Monday on the Nasdaq.
Tuesday January 23, 9:14 am ET
Novavax Up on Successful Preclinical Study of Bird Flu Vaccines; Nasdaq Declines
Among the most active stocks was Novavax Inc., which added 41 cents, or 10 percent, to $4.50 in premarket electronic trading after the Malvern, Pa., biotech drug developer said its virus-like particle vaccines were effective in preclinical studies in protecting against different strains of the H5N1 bird flu virus.
Studies involved two vaccines. One targets the Indonesia strain of avian flu and another targets the Vietnam strain.
The stock closed at $4.09 Monday on the Nasdaq.